Hepatitis B and D

Orinbayeva Zukhra Naurizbaevna, Nabidjonova Durdona Davron qizi

dc.contributor.author	Orinbayeva Zukhra Naurizbaevna, Nabidjonova Durdona Davron qizi
dc.date.accessioned	2022-12-13T11:30:29Z
dc.date.available	2022-12-13T11:30:29Z
dc.date.issued	2022-12-20
dc.identifier.citation	ISSN 2795-7675	en_US
dc.identifier.issn	2795-7675
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/5030
dc.description.abstract	In recent years, liver diseases have taken an important place among the main causes of premature disability and death of the population. Every year, more than 1 million people of the world are infected with liver diseases. Death due to viral hepatitis is increasing year by year. According to WHO data in 2015, viral hepatitis caused the death of 1.34 million people. 720,000 of them died from chronic liver diseases - liver cirrhosis and cancer, and 470,000 died from hepatocellular carcinoma (WHO, 2015y). In this article, the scientific work conducted on hepatitis B and D diseases on a global scale is studied, and their advantages over each other are explained in more detail.	en_US
dc.language.iso	en	en_US
dc.publisher	BOSTON	en_US
dc.relation.ispartofseries	УДК;16.33-002.44-06-006.6-022:579.842.17
dc.subject	Hepatitis B (GBV), Hepatitis D (GDV), pathogen, interferon-alpha	en_US
dc.title	Hepatitis B and D	en_US
dc.title.alternative	Hepatitis B and D	en_US
dc.type	Article	en_US